Indeed early studies in animal models demonstrated that an anti-VEGF monoclonal antibody in combination with the OXi4503 treatment prevented mobilization of precursor endothelial cells and resulted in significant tumor reduction [22]. The gene discussed is VEGFA; the disease is neoplasm.